Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

Previous Page

Next Page

Page Background

Understanding the resistance for sequence

Crizotinib

1st line

Next Gen.

1st line

Gainor – Cancer Disc 2016 (Courtesy of Prof. Besse, modified)